Ambrx Biopharma Inc - ADR logo

AMAM

Ambrx Biopharma Inc - ADR

$2.24

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ambrx Biopharma Inc - ADR post its latest quarter earnings

EPS Estimate Current Quarter
0
EPS Estimate Current Year
0

Highlights

EPS Estimate Current Quarter:

Ambrx Biopharma Inc - ADR’s earning per share (EPS) estimates for the current quarter stand at 0 - a NaN% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ambrx Biopharma Inc - ADR’s earning per share (EPS) estimates for the current year stand at 0.

Key Ratios

Key ratios of the Ambrx Biopharma Inc - ADR post its Q4 2021 earnings

Return on Assets (ROA)
-0.22
Return on Equity (ROE)
-0.42
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ambrx Biopharma Inc - ADR’s return on assets (ROA) stands at -0.22.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ambrx Biopharma Inc - ADR’s return on equity (ROE) stands at -0.42.

Dividend Per Share (DPS):

Ambrx Biopharma Inc - ADR declared 0 dividend per share during the earnings announcement for Q4 2021.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-03-31
0
-5.72
-Inf%

Company Information

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.

Organisation
Ambrx Biopharma Inc - ADR